Evidence map›Paper›PMID 37022168›Full record

ArticleJournal of clinical microbiology2023

Intrinsic Resistance to Colistin in the Genus

Sarah E Turbett, Ryan A Bronson, Colin J Worby, Graham E G McGrath, Emily Hodgkins, Margaret Becker, Barbara Belford, Lucyna Kogut, Elizabeth Oliver, Edward T Ryan and 3 more

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Sarah E Turbett *Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-3603-8110
Ryan A Bronson *Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Boston, Massachusetts, USA.
Colin J WorbyInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Boston, Massachusetts, USA.
Graham E G McGrathDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Emily HodgkinsDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Margaret BeckerDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Barbara BelfordDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Lucyna KogutDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Elizabeth OliverDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Edward T RyanDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Regina C LaRocqueDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Ashlee M Earl *Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Boston, Massachusetts, USA.
Virginia M Pierce *Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-3723-1326
Massachusetts General Hospital · USHarvard University · USBroad Institute · US

Funding

Viral Genomics: evolution, spread, and host interactionsU19AI110818 · NIAID · BROAD INSTITUTE, INC. · PI CUOMO, CHRISTINA A · 2014 to 2024
$66.5M
ACL HHS U01CK000490NCEZID CDC HHS U01 CK000633NIAID NIH HHS U19 AI110818
6 · The paper itself

Abstract

A bacterial species is considered to be intrinsically resistant to an antimicrobial when nearly all of the wild-type isolates (i.e., those without acquired resistance) exhibit minimum inhibitory concentration (MIC) values that are sufficiently high such that susceptibility testing is unnecessary, and that the antimicrobial should not be considered for therapy. Accordingly, knowledge of intrinsic resistance influences both the selection of treatment regimens and the approach to susceptibility testing in the clinical laboratory, where unexpected results also facilitate the recognition of microbial identification or susceptibility testing errors. Previously, limited data have suggested that

Indexed as

Anti-Infective AgentsHafniaAnti-Bacterial AgentsColistinEnterobacteriaceaeHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsAnti-Infective AgentsColistinantimicrobial resistancecolistinHafniaintrinsic resistance

Identifiers

PMID37022168
PMCPMC10204633
OpenAlexW4362657682

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.